Summary & Overview
HCPCS Level II J9144: Daratumumab 10 mg with Hyaluronidase, Subcutaneous Injection
HCPCS Level II code J9144 represents the subcutaneous combination product of daratumumab with hyaluronidase‑fihj, an oncology therapeutic used primarily in hematology/oncology care. Nationally, this code matters because it differentiates the subcutaneous formulation from intravenous alternatives, which can affect administration workflows, infusion suite time, and billing specificity across outpatient settings. Primary payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
Readers will learn what the code covers clinically and operationally, how it relates to other daratumumab codes, and what to expect in payer coverage considerations for outpatient oncology services. The publication provides concise benchmarks for coding and billing practice, notes common clinical contexts where the product is used in multiple myeloma and related plasma cell disorders, and identifies areas where policy language or coding guidance typically applies. Any missing service-line details are noted as "Data not available in the input." The content is intended for healthcare billing managers, oncology practice administrators, and clinical coders seeking a clear, nationally relevant summary of HCPCS Level II code J9144 and its role in outpatient oncology billing.
Billing Code Overview
HCPCS Level II code J9144 describes an injection of daratumumab, 10 mg combined with hyaluronidase‑fihj. This code is used for administration of the subcutaneous formulation of daratumumab with hyaluronidase as part of medical oncology and hematology treatment regimens.
Service type: Medical oncology / Hematology
Typical site of service: Outpatient (e.g., Physician Office or Hospital Outpatient)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old patient with relapsed multiple myeloma presents to an outpatient oncology infusion center for administration of daratumumab with hyaluronidase. The patient has a recent oncology visit documenting progressive disease after prior therapy and an order for subcutaneous daratumumab with hyaluronidase. Nursing triage confirms premedication given per protocol, verifies vitals and allergy history, performs site selection, and prepares the HCPCS Level II code J9144 dose-specified syringes. The medication is administered in the physician office or hospital outpatient infusion suite, observation for infusion‑related reactions is performed, and the encounter, drug amount administered, and any discarded drug are documented in the medication administration record and the claim.
Coding Specifications
-
HCPCS Level II code:
J9144— Injection, daratumumab, 10 mg and hyaluronidase‑fihj. -
Common modifiers:
-
JW- Drug amount discarded/not administered to any patient. Use when a portion of the prepared biologic is discarded and documentation supports the discarded amount. -
59- Distinct Procedural Service. Use when a service or procedure that is not normally reported together is distinct because it was performed at a separate session or an identifiable separate procedure; documentation must support the distinct service. -
: